Haematologica
HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zinzani, P.
Right arrow Articles by Baccarani, M
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zinzani, P.
Right arrow Articles by Baccarani, M
Haematologica, Vol 89, Issue 3, 309-313
Copyright © 2004 by Ferrata Storti Foundation

Journal Article

Long-term follow-up of front-line treatment of hairy cell leukemia with 2-chlorodeoxyadenosine

PL Zinzani, M Tani, E Marchi, V Stefoni, L Alinari, G Musuraca, A Gabriele, S Pileri, and M Baccarani

Institute of Hematology and Medical Oncology L. e A. Seragnoli, University of Bologna, Italy. plzinzo@med.unibo.it

BACKGROUND AND OBJECTIVES: Although remission of hairy cell leukemia (HCL) after treatment with 2-chlorodeoxyadenosine (2-CdA) appears to be long lasting, few reports currently provide results from follow-up exceeding 5 years. DESIGN AND METHODS: We reviewed our HCL patients treated with front-line 2-CdA (by 2-hour infusion) either for 5 consecutive days at 0.14 mg/kg/day (daily subset, n=21) or once a week at 0.14 mg/kg for 5 cycles (weekly subset, n=16). RESULTS: Of the 37 eligible patients, 30 (81%) achieved complete response (CR) and 7 (19%) partial response (PR) (overall response rate, 100%); identical response rates were recorded in the daily and weekly subsets. After a median follow-up of 122 months (range, 54-156), the overall relapse rate was 27% (8/30): 24% (4/17) had relapsed in the subset treated daily whereas 30% (4/13) had done so in the subset treated weekly (p=ns). The projected 13-year overall and the relapse-free survivals are 96% and 52%, respectively. In terms of hematologic toxicity, the weekly 2-CdA schedule was associated with significantly fewer cases of grade 3-4 neutropenia. INTERPRETATION AND CONCLUSIONS: In HCL patients, a single dose of 2-CdA induces a long-term CR. Over 90% of patients are alive 13 years later and over 50% of patients appear to be clinically cured by this treatment. The weekly schedule seems to be a safer option for neutropenic HCL patients, while apparently providing equivalent results in terms of response rates and long-term outcome.


This article has been cited by other articles:


Home page
 BloodHome page
T. Robak, K. Jamroziak, J. Gora-Tybor, J. Z. Blonski, M. Kasznicki, J. Dwilewicz-Trojaczek, E. Wiater, A. Zdunczyk, J. Dybowicz, A. Dmoszynska, et al.
Cladribine in a weekly versus daily schedule for untreated active hairy cell leukemia: final report from the Polish Adult Leukemia Group (PALG) of a prospective, randomized, multicenter trial
Blood, May 1, 2007; 109(9): 3672 - 3675.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
S. O. Wanko and C. de Castro
Hairy Cell Leukemia: An Elusive but Treatable Disease
Oncologist, July 1, 2006; 11(7): 780 - 789.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
P. Chadha, A. W. Rademaker, P. Mendiratta, B. Kim, D. M. Evanchuk, D. Hakimian, L. C. Peterson, and M. S. Tallman
Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA): long-term follow-up of the Northwestern University experience
Blood, July 1, 2005; 106(1): 241 - 246.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
Copyright © 2004 by the Ferrata Storti Foundation.